SCHEMBL5765652

SCHEMBL5765652

Fc1ccc(-c2[nH]cc(C3=CC4C=C(c5ccccc5)CN4CC3)c2-c2ccncc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.66
MAPK11 Q15759 3/20 0.66
GCGR P47871 4/20 0.40
MAPK13 O15264 2/20 0.38
MAPK12 P53778 2/20 0.38
ALOX5 P09917 1/20 0.38
RIPK3 Q9Y572 1/20 0.36
CSNK1D P48730 1/20 0.36
CSNK1E P49674 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5763973 0.88 MAPK14 (0.66) MAPK14MAPK11GCGRMAPK13MAPK12
SCHEMBL5764461 0.88 MAPK14 (0.66) MAPK14MAPK11GCGRMAPK13MAPK12
SCHEMBL5764567 0.85 MAPK14 (0.63) MAPK14MAPK11GCGRMAPK13MAPK12
SCHEMBL5765371 0.84 MAPK14 (0.61) MAPK14MAPK11GCGRMAPK13MAPK12
SCHEMBL5249865 0.83 MAPK14 (0.46) MAPK14MAPK11GCGRMAPK13MAPK12
SCHEMBL6222012 0.81 MAPK14 (0.65) MAPK14MAPK11GCGRMAPK13MAPK12
SCHEMBL5763394 0.81 MAPK14 (0.67) MAPK14MAPK11GCGRRIPK3
SCHEMBL5764416 0.81 MAPK14 (0.67) MAPK14MAPK11GCGRRIPK3
SCHEMBL6218157 0.81 MAPK14 (0.67) MAPK14MAPK11GCGRRIPK3
SCHEMBL5766469 0.80 MAPK14 (0.63) MAPK14MAPK11GCGRRIPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122666-B2 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-10-17 US claimed
EP-1377577-B1 PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES SANKYO CO (JP) 2006-06-14 EP claimed
US-20040054173-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2004-03-18 US claimed
US-7122666-B2 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-10-17 US disclosed
US-20060128756-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-06-15 US disclosed
EP-1377577-B1 PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES SANKYO CO (JP) 2006-06-14 EP disclosed
US-20050283006-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2005-12-22 US disclosed
US-20040054173-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128756-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses IL2, IL1A, IL1B MAPK14 3902/4885MAPK11 3630/4885GCGR 3466/4885
US-20050283006-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses IL2, CNKSR1, IL1A MAPK14 4157/4885MAPK11 3723/4885GCGR 2716/4885
US-20040054173-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses IL2, IL1B, IL1A MAPK14 3593/4885MAPK11 3364/4885GCGR 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.